NS Pharma, Inc.

15 articles with NS Pharma, Inc.

• VILTEPSO® (viltolarsen) injection Interim Long-Term Clinical Trial Data Scheduled for Presentation at the Child Neurology Society Annual Meeting

  9/22/2021

   NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), announced today an electronic poster presentation on long-term efficacy and safety data (interim analysis at 109 weeks) from the open-label extension (up to 192 weeks) of a Phase 2 study of VILTEPSO® (viltolarsen) injection at the Child Neurology Society 50th Annual Meeting.

• VILTEPSO® (viltolarsen) injection Interim Long-Term Clinical Trial Data Scheduled for Presentation at the World Muscle Society 2021 Virtual Conference

  9/17/2021

  NS Pharma, Inc. announced today an electronic poster presentation on long-term efficacy and safety data (interim analysis at 109 weeks) from the open-label extension (up to 192 weeks) of a Phase 2 study of VILTEPSO® (viltolarsen) injection at the World Muscle Society 2021 Virtual Conference being held September 20–24.

• VILTEPSO® (viltolarsen) injection: Long-Term Efficacy and Safety Data Presented at the PPMD 2021 Virtual Annual Conference

  7/1/2021

  NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru Nakai), announced that new long-term efficacy and safety data based on interim analyses at 109 weeks from the open-label extension trial of a Phase 2 study of VILTEPSO® (viltolarsen) injection were presented at the PPMD 2021 Annual Conference.

• Webcast of VILTEPSO® (viltolarsen) injection: Long-Term Data Scheduled for Presentation at the PPMD 2021 Virtual Annual Conference

  6/21/2021

  NS Pharma, Inc. announces a webcast during the PPMD 2021 Virtual Annual Conference held from June 23 to 26 .

• VILTEPSO® (viltolarsen) injection Long-Term Clinical Trial Data to be Presented at the PPMD 2021 Virtual Annual Conference

  5/12/2021

  NS Pharma, Inc., a wholly owned subsidiary of Nippon Shinyaku Co., Ltd., announced that new, long-term efficacy and safety data from the open-label extension of a Phase 2 study of VILTEPSO® injection will be presented at the PPMD 2021 Annual Conference being held virtually from June 23-26.

• NS Pharma's VILTEPSO® (viltolarsen) Receives Permanent J-code from Centers for Medicare and Medicaid Services

  4/1/2021

  NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Shigenobu Maekawa), announced that the J-code assigned by the Centers for Medicare and Medicaid Services (CMS) for VILTEPSO® (viltolarsen) injection is effective today.

• VILTEPSO™ (viltolarsen) injection Now Commercially Available in the U.S.

  8/19/2020

   NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka ), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Shigenobu Maekawa ), announced today that VILTEPSO™ (viltolarsen) injection is now commercially available in the U.S. On August 12, 2020 , the U.S. Food & Drug Administration (FDA) approve

• 

  FDA Approves NS Pharma’s Viltepso for Duchenne Muscular Dystrophy

  8/13/2020

  The U.S. Food and Drug Administration (FDA) approved another therapy for Duchenne muscular dystrophy (DMD), this time NS Pharma’s Viltepso (viltolarsen).

• NS Pharma's VILTEPSO™ (viltolarsen) injection Now FDA-Approved in the U.S. for the Treatment of Duchenne Muscular Dystrophy in Patients Amenable to Exon 53 Skipping Therapy

  8/12/2020

  Patients taking VILTEPSO showed an increase in dystrophin expression to an average of 5.9% of normal after 20-24 weeks of treatment.

• NS Pharma Announces Launch of Patient Support Hub

  7/7/2020

  NS Pharma, Inc., a wholly owned subsidiary of Nippon Shinyaku Co., Ltd., announced the launch of NS Support for patients with Duchenne muscular dystrophy and their healthcare providers.

• NS Pharma Announces Publication of Clinical Trial Data for Viltolarsen in DMD Patients in JAMA Neurology

  5/26/2020

  NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President Shigenobu Maekawa), announced today that JAMA Neurology has published  results from a clinical  trial of viltolarsen, an investigational agent being evaluated in Duchenne muscular dystrophy (DMD) patients who are amenable to exon 53 skipping therapy.

• NS Pharma, Inc. To Present At J.P. Morgan Healthcare Conference

  1/6/2015

• NS Pharma, Inc. To Present At J.P. Morgan Healthcare Conference

  1/6/2015

• NS Pharma, Inc. Celebrates 20th Anniversary Of Initial Public Offering With NASDAQ Opening Bell Ceremony

  5/27/2014

• The Day In Review: Preos From NS Pharma, Inc. Gets Approvable Letter

  3/10/2006